BIOERODIBLE SILICON-BASED DELIVERY VEHICLES FOR DELIVERY OF THERAPEUTIC AGENTS
This invention discloses bioerodible delivery compositions for delivering peptide therapeutic agents. The delivery compositions comprise a porous silicon-based carrier material loaded with the therapeutic agent. The delivery compositions may be used in vitro or in vivo to deliver the therapeutic agent, preferably in a controlled fashion over an intended period of time such as over multiple days, weeks or months. The delivery compositions may be used for treating or preventing conditions of a patient such as chronic diseases.
1 . A sustained release drug delivery composition comprising:
a porous carrier material comprising a silicon-based compound; and
at least one therapeutic agent associated with the carrier material, wherein the at least one therapeutic agent includes adrenocorticotropic hormone (ACTH) or an analog thereof.
2 . The delivery composition according to claim 1 , wherein the silicon-based compound comprises one or more of: porous silicon, polycrystalline silicon, resorbable silicon or bio-erodible silicon.
3 . The delivery composition according to claim 2 , wherein the silicon-based compound comprises porous silicon, and the porous silicon is mesoporous silicon.
4 . The delivery composition according to claim 1 , wherein the silicon-based compound has a silica or silicon oxide surface.
5 . The delivery composition according to claim 1 , wherein the silicon-based compound is amorphous silica.
6 . The delivery composition according to claim 1 , wherein the at least one therapeutic agent includes an ACTH analog selected from corticotropin, tetracosactide, or cosyntropin.
7 . The delivery composition according to claim 1 , wherein the carrier material is sized for injection through a needle.
8 . A method of making the delivery composition according to claim 2 , comprising introducing the at least one therapeutic agent into the pores of the carrier material.
9 . A method of administering at least one therapeutic agent to a mammal in need thereof, comprising administering a composition according to claim 1 to a mammal.
10 . The method according to claim 9 , wherein the at least one therapeutic agent is adsorbed to a surface of the carrier material.
11 . The method according to claim 9 , wherein the composition delivers the at least one therapeutic agent locally to a specific site of the mammal.
12 . (canceled)
13 . The delivery composition according to claim 1 , wherein the average pore size of the porous carrier material is about 1 nm to about 10 nm.
14 . The delivery composition according to claim 13 , wherein the average pore size of the porous carrier material is about 5 nm to about 10 nm.
15 . The delivery composition according to claim 1 , wherein the adrenocorticotropic hormone or analog thereof has a molecular weight of about 1,000 amu to about 10,000 amu.
16 . The delivery composition according to claim 15 , wherein the adrenocorticotropic hormone or analog thereof has a molecular weight of about 2,000 amu to about 5,000 amu.
17 . The delivery composition according to claim 1 , wherein the adrenocorticotropic hormone or analog thereof is stable at 25° C. for at least 6 months.
18 . The delivery composition according to claim 1 , wherein the adrenocorticotropic hormone or analog thereof has a half-life that is at least twice as long as the adrenocorticotropic hormone or analog thereof outside of the carrier material under the same conditions.
19 . The delivery composition according to claim 1 , wherein the composition is configured to release the adrenocorticotropic hormone or analog thereof over the course of about one month to about one year.
20 . A sustained release drug delivery composition, comprising a porous silicon-based carrier material and a therapeutic agent disposed in pores of the carrier material, wherein:
the average pore size of the carrier material is about 1 nm to about 10 nm;
the therapeutic agent is adrenocorticotropic hormone or an analog thereof;
the therapeutic agent has a molecular weight of about 2,000 amu to about 5,000 amu; and
the composition is configured to release the therapeutic agent over the course of about one month to about one year.
21 . The delivery composition according to claim 20 , wherein the carrier material is sized for injection through a needle.